SLS

Shares of SELLAS Life Sciences are exploding higher today, extending a multi-day rally that has pushed the stock well above its 50-day moving average. While there are no new company-specific announcements from the last 48 hours, the recent momentum follows a series of corporate governance updates and ongoing investor interest regarding the company's dual-path AML franchise. The stock's significant after-hours move suggests that market participants are continuing to price in the potential of the pivotal Phase 3 REGAL trial and the development of the SLS009 pipeline.